Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

Through the use of surrogate markers of efficacy, neoadjuvant studies may facilitate the implementation of new treatments into clinical practice. However, disease-free survival is the current standard outcome endpoint for registration of a novel treatment. The coupling of smaller neoadjuvant 'p...

Full description

Saved in:
Bibliographic Details
Main Authors: Snoj, Natasa, Bedard, Philippe L, de Azambuja, Evandro, Cardoso, Fatima, Piccart, Martine
Format: Artigo
Language:Inglês
Published: BioMed Central 2009
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2687702/
https://ncbi.nlm.nih.gov/pubmed/19216727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr2209
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items